Veracyte VCYT Biopharmaceutical and other revenue — Cost of Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Veracyte's biopharmaceutical and other revenue — cost of revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Veracyte's biopharmaceutical and other revenue — cost of revenue?
- Veracyte (VCYT) reported biopharmaceutical and other revenue — cost of revenue of $8K in Q1 2026.
- How has Veracyte's biopharmaceutical and other revenue — cost of revenue changed year-over-year?
- Veracyte's biopharmaceutical and other revenue — cost of revenue decreased by 99.7% year-over-year, from $2.7M to $8K.
- What is the long-term trend for Veracyte's biopharmaceutical and other revenue — cost of revenue?
- Over 4 years (2021 to 2025), Veracyte's biopharmaceutical and other revenue — cost of revenue has grown at a -5.9% compound annual growth rate (CAGR), from $9.65M to $7.58M.
- What does biopharmaceutical and other revenue — cost of revenue mean?
- This metric captures the direct costs associated with delivering biopharmaceutical services and research collaborations, including labor, materials, and overhead directly attributable to these contracts. Monitoring this figure helps assess the direct profitability and operational efficiency of the company's non-diagnostic revenue streams.